366 related articles for article (PubMed ID: 26575166)
1. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
Moran-Jones K; Gloss BS; Murali R; Chang DK; Colvin EK; Jones MD; Yuen S; Howell VM; Brown LM; Wong CW; Spong SM; Scarlett CJ; Hacker NF; Ghosh S; Mok SC; Birrer MJ; Samimi G
Oncotarget; 2015 Dec; 6(42):44551-62. PubMed ID: 26575166
[TBL] [Abstract][Full Text] [Related]
2. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
[TBL] [Abstract][Full Text] [Related]
3. High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.
Bareche Y; Pommey S; Carneiro M; Buisseret L; Cousineau I; Thebault P; Chrobak P; Communal L; Allard D; Robson SC; Mes-Masson AM; Provencher D; Lapointe R; Stagg J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771891
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
[TBL] [Abstract][Full Text] [Related]
6. Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.
Lu H; Kojima K; Battula VL; Korchin B; Shi Y; Chen Y; Spong S; Thomas DA; Kantarjian H; Lock RB; Andreeff M; Konopleva M
Ann Hematol; 2014 Mar; 93(3):485-492. PubMed ID: 24154679
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of connective tissue growth factor by three-dimensional matrix enhances ovarian carcinoma cell invasion.
Barbolina MV; Adley BP; Kelly DL; Shepard J; Fought AJ; Scholtens D; Penzes P; Shea LD; Stack MS
Int J Cancer; 2009 Aug; 125(4):816-25. PubMed ID: 19382180
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis.
Sakai N; Nakamura M; Lipson KE; Miyake T; Kamikawa Y; Sagara A; Shinozaki Y; Kitajima S; Toyama T; Hara A; Iwata Y; Shimizu M; Furuichi K; Kaneko S; Tager AM; Wada T
Sci Rep; 2017 Jul; 7(1):5392. PubMed ID: 28710437
[TBL] [Abstract][Full Text] [Related]
9. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
[TBL] [Abstract][Full Text] [Related]
10. Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition.
Zhu X; Zhong J; Zhao Z; Sheng J; Wang J; Liu J; Cui K; Chang J; Zhao H; Wong S
Oncotarget; 2015 Sep; 6(28):25320-38. PubMed ID: 26318291
[TBL] [Abstract][Full Text] [Related]
11. Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma.
Shimbo A; Kajiyama H; Tamauchi S; Yoshikawa N; Ikeda Y; Nishino K; Suzuki S; Niimi K; Sakata J; Kikkawa F
Oncol Rep; 2019 Dec; 42(6):2323-2332. PubMed ID: 31578579
[TBL] [Abstract][Full Text] [Related]
12. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
13. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model.
McCann CK; Growdon WB; Kulkarni-Datar K; Curley MD; Friel AM; Proctor JL; Sheikh H; Deyneko I; Ferguson JA; Vathipadiekal V; Birrer MJ; Borger DR; Mohapatra G; Zukerberg LR; Foster R; Macdougall JR; Rueda BR
PLoS One; 2011; 6(11):e28077. PubMed ID: 22140510
[TBL] [Abstract][Full Text] [Related]
15. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer.
Yamamura S; Matsumura N; Mandai M; Huang Z; Oura T; Baba T; Hamanishi J; Yamaguchi K; Kang HS; Okamoto T; Abiko K; Mori S; Murphy SK; Konishi I
Int J Cancer; 2012 Jan; 130(1):20-8. PubMed ID: 21503873
[TBL] [Abstract][Full Text] [Related]
16. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
17. The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.
Hua KT; Wang MY; Chen MW; Wei LH; Chen CK; Ko CH; Jeng YM; Sung PL; Jan YH; Hsiao M; Kuo ML; Yen ML
Mol Cancer; 2014 Aug; 13():189. PubMed ID: 25115793
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy.
Xia B; Hou Y; Chen H; Yang S; Liu T; Lin M; Lou G
Oncotarget; 2017 Mar; 8(12):19534-19546. PubMed ID: 28099946
[TBL] [Abstract][Full Text] [Related]
19. Connective tissue growth factor acts as a therapeutic agent and predictor for peritoneal carcinomatosis of colorectal cancer.
Lin BR; Chang CC; Chen RJ; Jeng YM; Liang JT; Lee PH; Chang KJ; Kuo ML
Clin Cancer Res; 2011 May; 17(10):3077-88. PubMed ID: 21558398
[TBL] [Abstract][Full Text] [Related]
20. Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity.
Shen YW; Zhou YD; Chen HZ; Luan X; Zhang WD
Trends Cancer; 2021 Jun; 7(6):511-524. PubMed ID: 33358571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
